Table 2. Immunohistochemical expression of EGFR and EGFR ligands and their co-expressions in 60 mCRC patients using the Fisher's exact test, FET.
| Variables | No. of positive tumours (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| % Positive tumour cells | Intensity | Location | |||||||
| > 5 | > 10 | > 20 | > 50 | 1+ | 2+ | 3+ | Mem | Cyto | |
| wtEGFR | 27 (44) | 23 (38) | 16 (26) | 8 (13) | 27 (44) | 1 (2) | 0 | 7 (12) | 27 (44) |
| EGFRvIII | 25 (41) | 25 (41) | 17 (28) | 12 (20) | 23 (38) | 1 (2) | 1 (2) | 0 | 25 (41) |
| Amphiregulin | 21 (34) | 16 (27) | 7 (12) | 5 (8) | 18 (30) | 3 (5) | 0 | 0 | 21 (34) |
| BTC | 43 (72) | 40 (67) | 34 (57) | 19 (32) | 18 (30) | 29 (48) | 1 (2) | 0 | 43 (72) |
| EGF | 19 (31) | 17 (28) | 12 (20) | 7 (12) | 20 (33) | 1 (2) | 0 | 0 | 19 (31) |
| Epigen | 41 (67) | 33 (54) | 25 (41) | 17 (28) | 33 (54) | 9 (15) | 1 (2) | 0 | 40 (66) |
| TGFα | 35 (58) | 33 (55) | 30 (50) | 26 (43) | 31 (52) | 11 (18) | 0 | 0 | 35 (58) |
| wtEGFR/Amph | 13 (22) | 11 (18) | 3 (5) | 2 (3) | 10 (17) | 0 | 0 | - | - |
| wtEGFR/BTC | 18 (30) | 13 (22) | 8 (13) | 2 (3) | 6 (10) | 0 | 0 | - | - |
| wtEGFR/EGF | 6 (10) | 4 (7) | 3 (5) | 0 | 8 (13) | 0 | 0 | - | - |
| wtEGFR/Epigen | 17 (28) | 11 (18) | 6 (10) | 1 (2) | 12 (20) | 0 | 0 | - | - |
| wtEGFR/TGFα | 16 (27) | 12 (20) | 8 (13) | 3 (5) | 13 (22) | 1 (2) | 0 | - | - |
| wtEGFR/1 ligand | 26 (43) | 22 (37) | 15 (25) | 7 (12) | 24 (40) | 1(2) | 0 | - | - |
| wtEGFR/ 2 ligands | 21 (35) | 17 (28) | 8 (13) | 6 (10) | 16 (27) | 0 | 0 | - | - |
| wtEGFR/ 3 ligands | 14 (23) | 10 (17) | 4 (7) | 0 | 8 (13) | 0 | 0 | - | - |
| wtEGFR/ 4 ligands | 9 (15) | 2 (3) | 0 | 0 | 1 (2) | 0 | 0 | - | - |
Abbreviations: Mem, Membranous; Cyt, Cytoplasmic
P-value of ≤ 0.05 was considered significant